<?xml version="1.0" encoding="UTF-8"?>
<p id="p0160">Taken together, SARS-coronaviruses inhibit a number of mitochondrial antiviral defense mechanisms, including the reduction of interferon activation. It is known that pretreatment with interferon I/III is beneficial in SARS-CoV infection, but the protective effect may be even higher in SARS-CoV-2 (
 <xref rid="bib117" ref-type="bibr">Vabret etÂ al., 2020</xref>), suggesting similar or aggravated impairment of interferon activation in COVID-19.
</p>
